Woodline Partners’s Solid Biosciences SLDB Stock Holding History

Woodline Partners’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.73M	Buy	674,076 +179,000	+36%	+$1.36M	0.02%	618
2026 Q1	$3.56M	Buy	495,076 +178,253	+56%	+$1.15M	0.01%	723
2025 Q4	$1.79M	Sell	316,823 -315,000	-50%	-$1.71M	0.01%	781
2025 Q3	$3.9M	Hold	631,823	–	–	0.02%	613
2025 Q2	$3.08M	Hold	631,823	–	–	0.02%	651
2025 Q1	$2.34M	Buy	+631,823	New	+$2.71M	0.02%	642

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's SLDB Position: Q2 2026 in Review

Woodline Partners increased its Solid Biosciences (SLDB) stake by 36% in Q2 2026, buying an estimated $1.36M and bringing the position to 674,076 shares worth $6.73M. The position accounts for 0.02% of the portfolio, ranked #618.

Woodline Partners first reported a position in SLDB in Q1 2025 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Woodline Partners held 674,076 shares of Solid Biosciences worth $6.73M as of Q2 2026.
Woodline Partners bought 179,000 Solid Biosciences shares in Q2 2026, an estimated $1.36M.
Solid Biosciences made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #618 holding.
Woodline Partners first reported a position in Solid Biosciences in Q1 2025 and has held it in 6 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.